← Oncology Approval Tracker

FDA DECISION ·

Riabni

rituximab-arrx · Amgen

Biosimilar approvalBiosimilarNon-Hodgkin lymphoma and chronic lymphocytic leukemia
Open LinkedIn brief ↓

1 min read · estimated

Sources

APPROVED USE

What FDA approved

Rituxan biosimilar for adults with specified CD20-positive follicular or low-grade B-cell lymphoma, previously untreated CD20-positive diffuse large B-cell lymphoma with chemotherapy, or CD20-positive chronic lymphocytic leukemia with fludarabine and cyclophosphamide.

LAMPGEN ANALYSIS

Why it matters

Added another approved rituximab biosimilar for established oncology uses.

What research teams should watch

Record the exact biologic and preserve hepatitis B screening and infusion reaction procedures.

PRIMARY RECORDS

Sources